Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.

par Caroline Schmidbauer, Michael Schwarz, Angelika Schütz, Raphael Schubert, Cornelia Schwanke, Enisa Gutic, Roxana Pirker, Tobias Lang, Thomas Reiberger, Hans Haltmayer, Michael Gschwantler
Publié 2021